Bass E P, Gill M A, Beckenhauer W H
J Am Vet Med Assoc. 1982 Nov 1;181(9):909-13.
A modified live, canine origin parvovirus vaccine was tested for safety, efficacy, and clinical performance. The vaccine protected dogs from challenge of immunity with canine parvovirus (CPV) that caused clinical illness in all nonvaccinated dogs. Vaccinates all developed CPV serum neutralization antibody titers, with a mean value of 1,664. Challenge virus was not isolated from vaccinates, but feces from nonvaccinated dogs were CPV-positive for up to 4 days following challenge. In a pathogenicity test, dogs inoculated orally with 10 times the label dose remained clinically normal. In a reversion-to-virulence test, the vaccine strain remained nonpathogenic through 6 passages in seronegative test dogs. An immunologic interference test demonstrated that test dogs developed antibodies for all antigens in a combined canine distemper virus-adenovirus 2-parainfluenza virus-parvovirus vaccine and a Leptospira interrogans serovars canicola and icterohaemorrhagiae bacterin. A total of 1,796 doses of the multivalent preparation was administered in a field study, with veterinary practitioners reporting 36 local and 5 generalized reactions.
对一种源自犬类的改良活细小病毒疫苗进行了安全性、有效性及临床性能测试。该疫苗可保护犬类免受犬细小病毒（CPV）攻击，未接种疫苗的犬类受到该病毒攻击会出现临床病症。接种疫苗的犬只均产生了CPV血清中和抗体效价，平均值为1664。在接种疫苗的犬只中未分离出攻击病毒，但在受到攻击后的4天内，未接种疫苗犬只的粪便CPV检测呈阳性。在致病性试验中，口服剂量为标签剂量10倍的犬只仍保持临床正常。在返强试验中，疫苗毒株在血清阴性的试验犬中传代6次后仍无致病性。免疫干扰试验表明，试验犬在接种犬瘟热病毒-腺病毒2-副流感病毒-细小病毒联合疫苗以及犬钩端螺旋体犬型和出血黄疸型血清型菌苗后，对所有抗原均产生了抗体。在一项现场研究中总共接种了1796剂多价制剂，兽医报告有36例局部反应和5例全身反应。
